The present invention provides an eco-friendly smart photosensitizer comprising a conjugate of hydroxypropyl methylcellulose and porfimer sodium photosensitizer, and a photo-stem cell therapy product comprising the photosensitizer. The photosensitizer of the present invention can be advantageously used in various fields including anticancer therapy, stem cell therapy, and the like, without side effects.

The present invention provides an eco-friendly smart photosensitizer comprising a conjugate of hydroxypropyl methylcellulose and porfimer sodium photosensitizer, and a photo-stem cell therapy product comprising the photosensitizer. The photosensitizer of the present invention can be advantageously used in various fields including anticancer therapy, stem cell therapy, and the like, without side effects.

Provided are: a hyaluronic acid derivative composition that comprises (A) a hyaluronic acid derivative having a steryl group introduced therein; and (B) a polar group-containing compound having at least one functional group selected from the group consisting of hydroxy group, carboxy group, amino group, amide group, carbamate group, urea group and thiol group, wherein the steryl group has been introduced at a ratio of 0.1% or more and less than 35% relative to the hyaluronic acid derivative (A); a pharmaceutical composition that contains the hyaluronic acid derivative composition as a carrier; and a hyaluronic acid derivative-drug conjugate composition wherein, in the hyaluronic acid derivative composition, one or more drugs are conjugated to the hyaluronic acid derivative (A).

Provided are: a hyaluronic acid derivative composition that comprises (A) a hyaluronic acid derivative having a steryl group introduced therein; and (B) a polar group-containing compound having at least one functional group selected from the group consisting of hydroxy group, carboxy group, amino group, amide group, carbamate group, urea group and thiol group, wherein the steryl group has been introduced at a ratio of 0.1% or more and less than 35% relative to the hyaluronic acid derivative (A); a pharmaceutical composition that contains the hyaluronic acid derivative composition as a carrier; and a hyaluronic acid derivative-drug conjugate composition wherein, in the hyaluronic acid derivative composition, one or more drugs are conjugated to the hyaluronic acid derivative (A).

A nanoparticle comprising chemically modified heparin, wherein the heparin has been chemically modified by attaching hydrophobic moieties to functional groups of the heparin, said functional groups being selected from hydroxy groups and carboxy groups, for use in the treatment or diagnosis of a brain disorder.

Drug-loaded microbead compositions include microbeads of a water-swellable polymer material and a complex of a carrier and a therapeutic agent chemically bonded to the carrier. The complex is embedded in the polymer material. The therapeutic agent is not chemically bonded to the water-swellable polymer material. The drug-loaded microbead composition has a water content of less than 1% by weight, based on the total weight of the drug-loaded microbead composition. The drug-loaded microbead composition may be rehydrated to form an embolization composition for use in in embolization therapy. Methods for preparing the drug-loaded microbead compositions and the embolization compositions include loading a therapeutic agent into a water-swellable polymer material to form microbeads, then removing water from the microbeads.

Provided herein are antibodies and antigen-binding fragments that bind MSR1 and methods of use thereof. According to certain embodiments, the antibodies bind human MSR1 with high affinity. In certain embodiments, the antibodies bind MSR1 without blocking, or blocking less than 90%, of modified LDL binding to MSR1. In some embodiments, the antibodies bind cell surface expressed-MSR1 and are internalized. The antibodies of the invention may be fully human antibodies. The invention includes anti-MSR1 antibodies, or antigen-binding fragments thereof, conjugated to drugs or therapeutic compounds.

Provided herein are antibodies and antigen-binding fragments that bind MSR1 and methods of use thereof. According to certain embodiments, the antibodies bind human MSR1 with high affinity. In certain embodiments, the antibodies bind MSR1 without blocking, or blocking less than 90%, of modified LDL binding to MSR1. In some embodiments, the antibodies bind cell surface expressed-MSR1 and are internalized. The antibodies of the invention may be fully human antibodies. The invention includes anti-MSR1 antibodies, or antigen-binding fragments thereof, conjugated to drugs or therapeutic compounds.

A method is described for producing a pneumococcal capsular polysaccharide protein conjugate in which one or more activated pneumococcal polysaccharides of particular pneumococcal serotypes and carrier protein are separately lyophilized, the separately lyophilized polysaccharides and carrier protein are separately reconstituted in an organic solvent, and the reconstituted polysaccharide and carrier protein are then combined together by Tee-mixing and conjugated together to produce polysaccharide carrier protein conjugates. A plurality of conjugates, each comprising polysaccharides of a particular serotype, may be used to produce multivalent pneumococcal immunogenic compositions having a combination of conjugates for use in vaccines.

A method is described for producing a pneumococcal capsular polysaccharide protein conjugate in which one or more activated pneumococcal polysaccharides of particular pneumococcal serotypes and carrier protein are separately lyophilized, the separately lyophilized polysaccharides and carrier protein are separately reconstituted in an organic solvent, and the reconstituted polysaccharide and carrier protein are then combined together by Tee-mixing and conjugated together to produce polysaccharide carrier protein conjugates. A plurality of conjugates, each comprising polysaccharides of a particular serotype, may be used to produce multivalent pneumococcal immunogenic compositions having a combination of conjugates for use in vaccines.